Kenneth C Anderson
Overview
Explore the profile of Kenneth C Anderson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
839
Citations
51136
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Morelli E, Ribeiro C, Rodrigues S, Gao C, Socciarelli F, Maisano D, et al.
Clin Cancer Res
. 2025 Mar;
PMID: 40053701
Purpose: In multiple myeloma (MM), tumor cells reprogram metabolic pathways to sustain growth and monoclonal immunoglobulin production. This study examines acetyl-CoA carboxylase 1 (ACC1), the enzyme driving the rate-limiting step...
2.
Shi Q, Paiva B, Pederson L, Dimier N, Talpes E, Prior T, et al.
J Clin Oncol
. 2025 Feb;
:JCO2402020.
PMID: 39938021
Purpose: Newly approved drugs and combinations treating multiple myeloma (MM) have resulted in substantial improvements in patients' survival. To deliver rapid access to newer therapies, an earlier end point to...
3.
Richardson P, Perrot A, San-Miguel J, Beksac M, Spicka I, Leleu X, et al.
Future Oncol
. 2025 Jan;
21(6):653-663.
PMID: 39851267
No abstract available.
4.
Waldschmidt J, Sotudeh N, Arora S, Vijaykumar T, Anand P, Stuart H, et al.
Blood Adv
. 2025 Jan;
9(5):1132-1136.
PMID: 39813623
No abstract available.
5.
Nadeem O, Aranha M, Redd R, Timonian M, Magidson S, Lightbody E, et al.
Nat Commun
. 2025 Jan;
16(1):358.
PMID: 39753553
Early therapeutic intervention in high-risk smoldering multiple myeloma (HR-SMM) has shown benefits, however, no studies have assessed whether biochemical progression or response depth predicts long-term outcomes. The single-arm I-PRISM phase...
6.
Yee A, Laubach J, Campagnaro E, Lipe B, Nadeem O, Friedman R, et al.
Blood Adv
. 2024 Dec;
9(5):1163-1170.
PMID: 39626297
Elotuzumab is a monoclonal antibody targeting signaling lymphocyte activation molecule F7 on plasma and natural killer cells, which enhances the activity of lenalidomide, pomalidomide, and bortezomib in multiple myeloma (MM)....
7.
Samur M, Aktas Samur A, Shah P, Park J, Park J, Fulciniti M, et al.
Blood
. 2024 Nov;
145(5):520-525.
PMID: 39571146
Nearly half of patients with multiple myeloma (MM) have hyperdiploidy (HMM) at diagnosis. Although HMM occurs early, the mutational processes before and after hyperdiploidy are still unclear. Here, we used...
8.
Bertamini L, Alberge J, Lee D, Lee D, El-Khoury H, Kim S, et al.
Blood
. 2024 Nov;
145(8):840-849.
PMID: 39571144
Detection of light chain (LC) monoclonal gammopathies (MGs) traditionally relies on serum free LC (FLC) κ, λ, and their ratio (κ/λ) reference ranges based on a mostly White population. We...
9.
Mitsiades C, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, et al.
Oncogene
. 2024 Nov;
44(4):269.
PMID: 39528816
No abstract available.
10.
Chauhan D, Hideshima T, Pandey P, Treon S, Teoh G, Raje N, et al.
Oncogene
. 2024 Sep;
43(40):3019.
PMID: 39237766
No abstract available.